<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5890137</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.00479</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Clapé</surname><given-names>Ariane</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/516630"/></contrib><contrib contrib-type="author"><name><surname>Muller</surname><given-names>Céline</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/534403"/></contrib><contrib contrib-type="author"><name><surname>Gatouillat</surname><given-names>Grégory</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/522653"/></contrib><contrib contrib-type="author"><name><surname>Le Jan</surname><given-names>Sébastien</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/515703"/></contrib><contrib contrib-type="author"><name><surname>Barbe</surname><given-names>Coralie</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/366326"/></contrib><contrib contrib-type="author"><name><surname>Pham</surname><given-names>Bach-Nga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/534415"/></contrib><contrib contrib-type="author"><name><surname>Antonicelli</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="author-notes" rid="fn001"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/27825"/></contrib><contrib contrib-type="author"><name><surname>Bernard</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/528927"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Laboratory of Dermatology, Faculty of Medicine, EA7319, University of Reims Champagne-Ardenne</institution>, <addr-line>Reims</addr-line>, <country>France</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Dermatology, Reims University Hospital, University of Reims Champagne-Ardenne</institution>, <addr-line>Reims</addr-line>, <country>France</country></aff><aff id="aff3"><sup>3</sup><institution>Laboratory of Immunology, Reims University Hospital, University of Reims Champagne-Ardenne</institution>, <addr-line>Reims</addr-line>, <country>France</country></aff><aff id="aff4"><sup>4</sup><institution>Clinical Research Unit, Reims University Hospital</institution>, <addr-line>Reims</addr-line>, <country>France</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Biological Sciences, Immunology, UFR Odontology, University of Reims Champagne-Ardenne</institution>, <addr-line>Reims</addr-line>, <country>France</country></aff><author-notes><fn fn-type="edited-by"><p><text><SENT sid="1" pm="."><plain>Edited by: Ralf J. </plain></SENT>
<SENT sid="2" pm="."><plain>Ludwig, University of Lübeck, Germany </plain></SENT>
</text></p></fn><fn fn-type="edited-by"><p><text><SENT sid="3" pm="."><plain>Reviewed by: Hiroshi Koga, Kurume University School of Medicine, Japan; Takashi Hashimoto, Osaka City University Graduate School of Medicine, Japan </plain></SENT>
</text></p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Frank Antonicelli, <email>frank.antonicelli@reims-reims.fr</email></corresp><fn fn-type="other" id="fn001"><p><text><SENT sid="4" pm="."><plain>†These authors have contributed equally to this work. </plain></SENT>
</text></p></fn><fn fn-type="other" id="fn002"><p><text><SENT sid="5" pm="."><plain>Specialty section: This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>479</elocation-id><history><date date-type="received"><day>12</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>22</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>Copyright © 2018 Clapé, Muller, Gatouillat, Le Jan, Barbe, Pham, Antonicelli and Bernard.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Clapé, Muller, Gatouillat, Le Jan, Barbe, Pham, Antonicelli and Bernard</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>Bullous pemphigoid (BP) is the most common autoimmune bullous disease and typically affects the elderly. </plain></SENT>
<SENT sid="7" pm="."><plain>Binding of specific autoantibodies to BP180/230 hemidesmosomal components induces an inflammatory response leading to skin blister formation. </plain></SENT>
<SENT sid="8" pm="."><plain>Unusual manifestations of BP include additional mucous membrane involvement, without pathophysiological knowledge associated to the formation of these lesions. </plain></SENT>
<SENT sid="9" pm="."><plain>We here performed a prospective study on series of consecutive BP patients with (n = 77) and without (n = 18) mucosal involvements at baseline to further investigate why some BP patients display mucosal lesion and other not. </plain></SENT>
<SENT sid="10" pm="."><plain>Analysis of disease activity showed that BP patients with mucosal involvement displayed a higher total BP Disease Area Index (BPDAI) score (P = 0.008), but also higher skin and blister/erosion BPDAI scores (P = 0.02 and P = 0.001, respectively). </plain></SENT>
<SENT sid="11" pm="."><plain>By contrast, the erythema/urticaria BPDAI score was identical between the two groups of patients. </plain></SENT>
<SENT sid="12" pm="."><plain>The erythema/urticaria BPDAI score, but not the blister/erosion BPDAI score, was correlated with the serum concentration of anti-BP180 NC16A autoantibodies in patients with mucosal involvement. </plain></SENT>
<SENT sid="13" pm="."><plain>In multivariate analysis, the absence of anti-BP230 autoantibody was the only factor independently associated with mucosal involvement (OR 7.8; 95% CI, 3.1–19.6) (P &lt; 0.0001). </plain></SENT>
<SENT sid="14" pm="."><plain>Analysis of the distribution of BP patients according to BPDAI scores revealed a shift toward higher blister/erosion BPDAI scores for BP patients with mucosal involvement. </plain></SENT>
<SENT sid="15" pm="."><plain>This study indicates that mucosal lesions are clinically mainly related to disease severity and immunologically to the absence of anti-BP230 antibodies. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>bullous pemphigoid</kwd><kwd>BP Disease Area Index</kwd><kwd>mucosal involvement</kwd><kwd>anti-BP230</kwd><kwd>autoantibodies</kwd></kwd-group></SecTag><counts><fig-count count="3"/><table-count count="4"/><equation-count count="0"/><ref-count count="46"/><page-count count="9"/><word-count count="6771"/></counts></article-meta></front><body><SecTag type="INTRO"><sec sec-type="introduction" id="S1"><title><text><SENT sid="16" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="17" pm="."><plain>Bullous pemphigoid (BP) is an autoimmune skin disease characterized by the binding of autoantibodies directed against two hemidesmosal proteins of the dermal–epidermal junction, namely BP180 and BP230 (1–6). </plain></SENT>
<SENT sid="18" pm="."><plain>The disease typically presents in the elderly with a generalized pruritic blistering eruption (7–9), which results from an inflammatory associated disruption of the dermal–epidermal junction induced by the binding of autoantibodies onto their targets. </plain></SENT>
<SENT sid="19" pm="."><plain>Clinical criteria for typical skin eruption of BP include the absence of associated external mucous membrane (almost exclusively oral) involvement, the absence of skin atrophy, and the absence of head and neck predominant involvement (10). </plain></SENT>
<SENT sid="20" pm="."><plain>However, clinical presentation of BP can be polymorphic, notably during the early, pre-bullous stage of the disease or in atypical variants, in which full-blown bullous lesions may be absent (11, 12). </plain></SENT>
<SENT sid="21" pm="."><plain>Beside, blisters and erosions arising on mucosal membranes, mainly within the oral cavity, may be observed in up to 20% of BP patients (6, 11–13), without identified pathophysiologic mechanism(s) associated with their development. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Despite the interest of the research community in always better understanding BP pathophysiology, no study demonstrated whether mucosal involvement occurred as a consequence of BP extent and severity or whether skin and mucosal lesions occurred concomitantly. </plain></SENT>
<SENT sid="23" pm="."><plain>Recently a clinical activity score named BP Disease Area Index (BPDAI) was proposed as an international consensus to evaluate both the disease extent and the location and type of skin lesions (9). </plain></SENT>
<SENT sid="24" pm="."><plain>The BPDAI also has the advantage to measure separate scores for skin and mucous membrane activity. </plain></SENT>
<SENT sid="25" pm="."><plain>Besides, the skin BPDAI score also evaluates separately the ultimate skin lesions, i.e., blisters/erosions, and the early, pre-bullous inflammatory skin lesions, i.e., urticaria/erythema, and their extent as well as the residual damages. </plain></SENT>
<SENT sid="26" pm="."><plain>Thus, such specific clinical score may be useful to better characterize those BP patients with associated mucosal involvement and improve their monitoring. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>Immunological and biological investigations in BP brought strong evidence that autoantibodies to BP180 are pathogenic and play a key role in subepidermal blister formation (14–20). </plain></SENT>
<SENT sid="28" pm="."><plain>Biopsy specimens from BP lesional skin exhibit dense inflammatory infiltration of eosinophils, basophils, neutrophils, lymphocytes, and mast cells in the dermis (1, 11, 13, 21, 22). </plain></SENT>
<SENT sid="29" pm="."><plain>Inflammatory cells infiltration and activation release cytokines and proteases that may create an auto-amplification loop reported to induce dermal–epidermal separation (23–27). </plain></SENT>
<SENT sid="30" pm="."><plain>However, variations in this pathophysiological process are still missing to explain why some BP patients will exhibit mucosal involvement and other not. </plain></SENT>
<SENT sid="31" pm="."><plain>In this matter, a more precise clinical characterization of BP patients with mucosal involvement may help to point out variations in the autoimmune and inflammatory responses in this particular BP subset. </plain></SENT>
</text></p><p><text><SENT sid="32" pm="."><plain>We here performed a prospective study on series of consecutive BP patients with and without mucosal involvement. </plain></SENT>
<SENT sid="33" pm="."><plain>To further understand why some BP patients display mucosal blisters or erosions and other not, we compared the total BPDAI and its different components with other clinical and immunological parameters of disease activity at baseline, including the number of daily new blisters and the anti-BP180 and anti-BP230 autoantibody titers. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="S2"><title><text><SENT sid="34" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="S2-1"><title><text><SENT sid="35" pm="."><plain>Study Patients and Design </plain></SENT>
</text></title><p><text><SENT sid="36" pm="."><plain>A prospective, single-center study was conducted in the Dermatology Department of the Reims University Hospital (French Referral Center for Autoimmune Bullous Diseases) between September 2013 and July 2017. </plain></SENT>
<SENT sid="37" pm="."><plain>The investigation was conducted under the approval of the Ethic Committee of the University Hospital of Reims (CNIL authorization DR-2013-320), and all of the subjects gave their informed and written consent before participating in the study in accordance with the Helsinki Declaration. </plain></SENT>
<SENT sid="38" pm="."><plain>Consecutive patients with newly diagnosed BP were included in this prospective study. </plain></SENT>
<SENT sid="39" pm="."><plain>Patients were diagnosed as having BP using the following criteria: clinical features typical of BP with the presence of at least three of four well-established criteria according to Vaillant et al. (10); subepidermal blister on skin biopsy, and deposits of IgG and/or C3 in a linear pattern along the epidermal basement membrane zone by direct immunofluorescence. </plain></SENT>
<SENT sid="40" pm="."><plain>Non-inclusion criteria were administration of a specific BP treatment for more than 2 days, pregnancy and expected survival after BP diagnosis shorter than 3 months. </plain></SENT>
</text></p></sec><sec id="S2-2"><title><text><SENT sid="41" pm="."><plain>Clinical Data Collection </plain></SENT>
</text></title><p><text><SENT sid="42" pm="."><plain>Clinical data recorded at baseline were gender, age, number of daily new blisters (determined over a 3-day period), and BPDAI. </plain></SENT>
<SENT sid="43" pm="."><plain>BPDAI was calculated according to the International Pemphigoid Committee recommendations (9). </plain></SENT>
<SENT sid="44" pm="."><plain>At baseline, BPDAI was recorded. </plain></SENT>
<SENT sid="45" pm="."><plain>The total BPDAI computes two scores: total BPDAI activity and total BPDAI damage. </plain></SENT>
<SENT sid="46" pm="."><plain>The total BPDAI activity score is the arithmetic sum of the three subcomponents—cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. </plain></SENT>
<SENT sid="47" pm="."><plain>The total BPDAI damage score is the arithmetic sum of the items rated regionally for damage caused by more permanent features such as post-inflammatory hyperpigmentation, scarring, and other. </plain></SENT>
<SENT sid="48" pm="."><plain>BPDAI also takes into account lesion number and size thresholds and skin lesions are rated based on the regions affected. </plain></SENT>
<SENT sid="49" pm="."><plain>Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity) and 0 to 12 for BPDAI damage, with higher scores indicating greater disease activity or damage. </plain></SENT>
<SENT sid="50" pm="."><plain>On the basis of previous literature (28), severe BP at baseline was defined as a total BPDAI score ≥56. </plain></SENT>
<SENT sid="51" pm="."><plain>BP patients who did not fulfill these criteria were classified as having moderate BP. </plain></SENT>
</text></p></sec><sec id="S2-3"><title><text><SENT sid="52" pm="."><plain>Anti-BP180 and Anti-BP230 Autoantibody Detection </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>Anti-BP180 and anti-BP230 autoantibodies were detected in serum and in blister fluids (BFs) using specific commercially available enzyme-linked immunosorbent assays (ELISAs) following the manufacturer’s instructions (MBL, Nagoya, Japan). </plain></SENT>
<SENT sid="54" pm="."><plain>Anti-BP180 and anti-BP230 antibodies’ detection was routinely performed on classically used dilution with no further dilution when titers were high. </plain></SENT>
<SENT sid="55" pm="."><plain>ELISA values were expressed as units per milliliters of serum (U/mL), and the 9 U/mL cut-off value recommended by the manufacturer was used in both anti-BP180 and anti-BP230 ELISAs (29–32). </plain></SENT>
</text></p></sec><sec id="S2-4"><title><text><SENT sid="56" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="57" pm="."><plain>Quantitative variables were described as mean ± SD and qualitative data as number and percentage. </plain></SENT>
<SENT sid="58" pm="."><plain>Kolmogorov–Smirnov test was performed to compare BP population distribution. </plain></SENT>
<SENT sid="59" pm="."><plain>The Kolmogorov–Smirnov test works by comparing the cumulative distribution of the two data sets and computes a P value that depends on the largest discrepancy between distributions. </plain></SENT>
<SENT sid="60" pm="."><plain>In contrast to Mann–Whitney test that is mostly sensitive to changes in the median, the Kolmogorov–Smirnov test is sensitive to changes in the shape, spread, or median of the two distributions. </plain></SENT>
<SENT sid="61" pm="."><plain>Chi2 tests were used for comparison between qualitative variables and nonparametric, Mann–Whitney tests for comparison between quantitative values. </plain></SENT>
<SENT sid="62" pm="."><plain>Owing to absence of normal distribution, comparisons between groups were performed using Spearman’s correlation coefficient to explore the relationship between continuous variables (BPDAI with immunological parameters, immunological parameters in serum with those in BF). </plain></SENT>
<SENT sid="63" pm="."><plain>A P value &lt;0.05 was considered statistically significant. </plain></SENT>
<SENT sid="64" pm="."><plain>Multivariate analyses were then performed using stepwise logistic regressions, with enter and removal limits set at 0.20 and factors significant at P = 0.20 included. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="S3"><title><text><SENT sid="65" pm="."><plain>Results </plain></SENT>
</text></title><sec id="S3-1"><title><text><SENT sid="66" pm="."><plain>Patient Characteristics </plain></SENT>
</text></title><p><text><SENT sid="67" pm="."><plain>A total of 97 patients with newly diagnosed BP were included in this study, 79 had typical clinical manifestations of BP and 18 presented with mucosal lesions in additional to skin blisters or erosions. </plain></SENT>
<SENT sid="68" pm="."><plain>In those BP patients with mucosal involvement, indirect immunofluorescence on salt-split skin was either positive with labeling of the epidermal side of the cleavage or negative. </plain></SENT>
<SENT sid="69" pm="."><plain>Using the same technique, two patients with positive immunolabeling on the dermal side only were subsequently excluded from the group with typical clinical BP presentation. </plain></SENT>
</text></p><p><text><SENT sid="70" pm="."><plain>The clinical characteristics of those 77 patients with typical BP features (81%, 51 women and 26 men) and of the 18 BP patients with mucosal involvement (19%, 11 women and 7 men) are shown in Table 1. </plain></SENT>
<SENT sid="71" pm="."><plain>In the 18 BP patients with unconventional mucosal involvement, oral mucosal lesions were observed in 17 cases and anogenital mucosae lesions in 1 case. </plain></SENT>
<SENT sid="72" pm="."><plain>Among the 17 patients with oral lesions, 1 patient also displayed anogenital mucosae involvement, and another 1 had concomitant pharyngeal mucosa lesions. </plain></SENT>
<SENT sid="73" pm="."><plain>In those 18 BP patients, neither conjunctival nor nasal mucosa involvement was observed. </plain></SENT>
<SENT sid="74" pm="."><plain>Occurrence of mucosal lesions was correlated neither with the gender (P = 0.78) nor with the age (P = 0.24) of patients. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="75" pm="."><plain>Clinical characteristics of patients with BP according to mucosal involvement. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>All BP patients </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>Patients without mucosal involvement </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>Patients with mucosal involvement </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>Pvalue </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>Number of patients (n) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>95 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>77 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>18 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>Sex ratio (F/M) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>1.88 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>1.96 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>1.57 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>0.68 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>Age, mean ± SD </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>81.7 ± 9.3 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>82.4 ± 8.9 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>78.7 ± 10.6 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>0.18 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>Patients with at least 10 daily new blisters,a n (%) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>45 (47.4) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>32 (41.6) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>13 (72.2) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>0.02 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>Number of daily new blisters,a mean ± SD </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>19.3 ± 29.8 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>17.6 ± 27.1 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>26.5 ± 39.4 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>0.07 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>BPDAI global score, mean ± SD </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>39.6 ± 27 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>35.8 ± 25.1 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>56.1 ± 29.2 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>0.008 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain> Activity of total skin involvement, mean ± SD </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>38.1 ± 26 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>35.1 ± 25 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>51.0 ± 26.8 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>0.021 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain> Blisters/erosions, mean ± SD </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>24.9 ± 17.6 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>22.1 ± 16.4 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>36.9 ± 17.6 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain> Erythema/urticaria, mean ± SD </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>13.2 ± 13.6 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>13 ± 13.3 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>14.1 ± 15.1 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>0.91 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain> Activity of mucosal involvement, mean ± SD </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>0.8 ± 2.4 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>4.0 ± 4.2 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain> Damage, mean ± SD </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>0.8 ± 2 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>0.7 ± 1.8 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>1.1 ± 2.6 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>0.78 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>Patients with severe disease according BPDAI,b n (%) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>24 (25) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>16 (20.8) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>8 (44.4) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>0.04 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="140" pm="."><plain>Subsets of BP patients with or without mucosal involvement were compared and P-value was obtained using Chi2 tests for comparison between qualitative variables and nonparametric, Mann–Whitney tests for comparison between quantitative values. </plain></SENT>
</text></p><fn id="tfn1"><p><text><SENT sid="141" pm="."><plain>aDetermined over a 3-day period. </plain></SENT>
</text></p></fn><fn id="tfn2"><p><text><SENT sid="142" pm="."><plain>bDetermined by BPDAI global score ≥56. </plain></SENT>
</text></p></fn><p><text><SENT sid="143" pm="."><plain>NA, not applicable; BP, bullous pemphigoid; BPDAI, BP Disease Area Index. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag></sec><sec id="S3-2"><title><text><SENT sid="144" pm="."><plain>Skin Disease Activity and Mucosal Involvement </plain></SENT>
</text></title><p><text><SENT sid="145" pm="."><plain>At the time of diagnosis, the number of patients with at least 10 daily new blisters was significantly higher in BP patients with mucosal involvement (P = 0.02) compared with patients with typical BP (Table 1), whereas the number of daily new blisters only tended to be higher in BP patients with mucosal involvement (P = 0.07). </plain></SENT>
</text></p><p><text><SENT sid="146" pm="."><plain>Total BPDAI mean score was 39.6 ± 27 at baseline in the whole BP population (Table 1). </plain></SENT>
<SENT sid="147" pm="."><plain>Based on a cut-off BPDAI value of 56 (see Materials and Methods), the percentage of BP patients with a severe disease was significantly lower in BP patients without mucosal involvement (20.8%) as compared to those with mucosal involvement (44.4%) (Table 1; P = 0.04). </plain></SENT>
<SENT sid="148" pm="."><plain>Deeper analysis showed that compared with BP patients with a typical disease, BP patients with mucosal involvement displayed a higher total BPDAI score (Table 1; P = 0.008), but also higher skin BPDAI and blister/erosion BPDAI scores (Table 1; P = 0.021 and P = 0.001, respectively). </plain></SENT>
<SENT sid="149" pm="."><plain>By contrast, the erythema/urticaria BPDAI score was not different between those two groups of patients (Table 1; P = 0.91). </plain></SENT>
</text></p><p><text><SENT sid="150" pm="."><plain>Analysis of the whole BP population distribution according to BPDAI score revealed that most patients had a mild to moderate disease and that the higher the BPDAI was, the lower the number of BP patients was (Figure 1A). </plain></SENT>
<SENT sid="151" pm="."><plain>Such a distribution was also observed for BP patients without mucosal involvement (Figure 1B), but was significantly different in BP patients with mucosal involvement (D = 0.6154; P = 0.008). </plain></SENT>
<SENT sid="152" pm="."><plain>Indeed, BP patients with mucosal involvement were evenly distributed from moderate to severe disease (Figure 1C). </plain></SENT>
<SENT sid="153" pm="."><plain>To further understand these discrepancies, the same analysis was then performed using the separate skin activity. </plain></SENT>
<SENT sid="154" pm="."><plain>The relative distribution according to the erythema/urticaria BPDAI score of BP patients without mucosal involvement superposed with the one of BP patients with mucosal involvement (D = 0.1667; P = 0.991) (Figure 2A). </plain></SENT>
<SENT sid="155" pm="."><plain>Analysis of the distribution according to the blisters/erosions BPDAI revealed a high percentage of patients with mucosal involvement when the BPDAI values increased and a low percentage of those patients when the BPDAI values were low (D = 0.33; P = 0.433) (Figure 2B). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="156" pm="."><plain>Distribution of the whole bullous pemphigoid (BP) patients (n = 95) (A) and of BP patients without (n = 77) (B) and with (n = 18) (C) mucosal involvement according to total BP Disease Area Index (BPDAI) values at the time of diagnosis. </plain></SENT>
<SENT sid="157" pm="."><plain>In the whole BP group and in the subgroup of BP without mucosal involvement, the number of BP included decrease when the values of the BPDAI increased, whereas BP patients with mucosal involvement were evenly distributed. </plain></SENT>
<SENT sid="158" pm="."><plain>Comparison of the cumulative distribution by the Kolmogorov–Smirnov test showed significant difference between BP patients with (C) and without (B) mucosal involvement (D = 0.6154; P = 0.008). </plain></SENT>
</text></p></caption><graphic xlink:href="fimmu-09-00479-g001"/></fig></SecTag><SecTag type="FIG"><fig id="F2" position="float"><label>Figure 2</label><caption><p><text><SENT sid="159" pm="."><plain>Distribution of both bullous pemphigoid (BP) patients with (white column) and without (gray column) mucosal involvement according to erythema/urticaria BP Disease Area Index (BPDAI) values (A) and blisters/erosions BPDAI values (B) at the time of diagnosis. </plain></SENT>
<SENT sid="160" pm="."><plain>No statistical differences were observed between the distributions of these two BP groups according to the Kolmogorov–Smirnov test, although a clear different distribution could be visualized within the low (0–19) and within the high (50–79) values of the blisters/erosions BPDAI values (B). </plain></SENT>
</text></p></caption><graphic xlink:href="fimmu-09-00479-g002"/></fig></SecTag></sec><sec id="S3-3"><title><text><SENT sid="161" pm="."><plain>Immunological Profiles and Mucosal Involvement </plain></SENT>
</text></title><p><text><SENT sid="162" pm="."><plain>In the aim to analyze the clinical features through the BPDAI scores with regards to the autoimmune response, we first measured anti-BP180 and anti-BP230 autoantibody concentrations in the BF of patients with BP. </plain></SENT>
<SENT sid="163" pm="."><plain>Anti-BP180 and anti-BP230 antibodies were detected in the BF of 32 (86.5%) and 16 (43.2%) patients with a mean titer of 79.4 ± 51.2 and 31.2 ± 40.3 U/mL, respectively (Table 2A). </plain></SENT>
<SENT sid="164" pm="."><plain>Subgroup analysis of BP patients with and without mucosal involvement showed no significant difference both within the number of BP patients who produced these antibodies and within the mean BF titer related to each antibody. </plain></SENT>
<SENT sid="165" pm="."><plain>We then investigated whether serum autoantibody concentrations reflected those measured in the BF of the same patients to seek a relationship between BPDAI scores and autoantibody production in the whole BP patients included. </plain></SENT>
<SENT sid="166" pm="."><plain>Anti-BP180 and anti-BP230 antibodies titers within the BF were highly and significantly correlated with those measured in the serum (r = 0.78 and r = 0.73; P &lt; 0.0001, respectively) (Table 2B). </plain></SENT>
<SENT sid="167" pm="."><plain>Such a correlation was also found for the anti-BP180 antibody titers within the two subsets of patients with or without mucosal involvement (r = 0.74 and r = 0.89; P &lt; 0.0001 and P = 0.01, respectively) (Table 2B). </plain></SENT>
<SENT sid="168" pm="."><plain>Anti-BP230 antibody titers in BF from typical BP patients were highly and significantly correlated with those measured in the serum of these patients (r = 0.74; P &lt; 0.0001), whereas only a high tendency was found for BP patients with mucosal involvement (r = 0.75; P = 0.07) (Table 2B). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><text><SENT sid="169" pm="."><plain>Blister fluid (BF) immunological characteristics (A) and correlation between serum and BF autoantibody titers (B) in patients with BP according to mucosal involvement. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>All BP patients </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>Patients without mucosal involvement </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>Patients with mucosal involvement </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>Pvalue </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="top" colspan="5" rowspan="1"><text><SENT sid="174" pm="."><plain>(A) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><text><SENT sid="175" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>Number of patients (n)a </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>37 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>30 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>7 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>BF anti-BP180 NC16A </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>Number of patients with titer ≥9 U/mL, n (%) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>32 (86.5) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>26 (86.7) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>6 (85.7) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>0.95 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>Mean value ± SD (U/mL) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>79.4 ± 51.2 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>78.5 ± 51.8 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>83.5 ± 52.2 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>0.66 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>BF anti-BP230 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>Number of patients with titer ≥9 U/mL, n (%) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>16 (43.2) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>14 (46.7) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>2 (28.7) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>0.38 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>Mean value ± SD (U/mL) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>31.2 ± 40.3 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>34.2 ± 41.5 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>18.2 ± 34.2 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>0.65 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><text><SENT sid="203" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><text><SENT sid="204" pm="."><plain>(B) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><text><SENT sid="205" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>Number of patientsa </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>37 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>30 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>7 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>Anti-BP180 NC16A </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>r = 0.78 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>r = 0.74 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>r = 0.89 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>P = 0.01 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>Anti-BP230 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>r = 0.73 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>r = 0.74 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>r = 0.75 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>P = 0.07 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><text><SENT sid="224" pm="."><plain>Subsets of BP patients with or without mucosal involvement were compared and P-value was calculated using Chi2 tests for comparison between qualitative variables and nonparametric, Mann–Whitney tests for comparison between quantitative values. </plain></SENT>
<SENT sid="225" pm="."><plain>Spearman’s correlation coefficient was used to explore the relationship between immunological parameters in serum with those in BF. </plain></SENT>
</text></p><fn id="tfn3"><p><text><SENT sid="226" pm="."><plain>aPatient for whom BF and serum anti-BP180 NC16A and anti-BP230 ELISA values were available. </plain></SENT>
</text></p></fn><p><text><SENT sid="227" pm="."><plain>NA, not applicable; BP, bullous pemphigoid; ELISA, enzyme-linked immunosorbent assay. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="228" pm="."><plain>Anti-BP180 antibodies were found in the serum of 77 patients (81.9%) with a mean titer of 63.9 ± 50.8 U/mL (Table 3). </plain></SENT>
<SENT sid="229" pm="."><plain>Subgroup analysis of BP patients with and without mucosal involvement showed no significant difference both within the number of BP patients who produced anti-BP180 antibodies and within the mean serum titer for this autoantibody (Table 3). </plain></SENT>
<SENT sid="230" pm="."><plain>In BP patients without mucosal involvement at baseline, serum anti-BP180 ELISA values were significantly correlated with all BPDAI scores except mucosal BPDAI, i.e., total, skin, blister/erosion, and erythema/urticaria BPDAI scores (P &lt; 0.0001, Figures 3A–D, Table 4A). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><text><SENT sid="231" pm="."><plain>Serum immunological characteristics of patients with BP according to mucosal involvement. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>All BP patients </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>Patients without mucosal involvement </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>Patients with mucosal involvement </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Pvalue </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="top" colspan="5" rowspan="1"><text><SENT sid="236" pm="."><plain>Serum anti-BP180 NC16A </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>Number of patients (n)a </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>94 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>76 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>18 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>Number of patients with titer ≥9 U/mL, n (%) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>77 (81.9) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>62 (81.6) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>15 (83.3) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>0.86 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>Mean value ± SD (U/mL) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>63.9 ± 50.8 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>62 ± 50.1 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>71.9 ± 54.4 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>0.53 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><text><SENT sid="252" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><text><SENT sid="253" pm="."><plain>Serum anti-BP230 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>Number of patients (n)b </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>93 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>75 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>18 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>Number of patients with titer ≥9 U/mL, n (%) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>44 (47.3) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>39 (52) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>5 (27.8) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>0.06 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>Mean value ± SD (U/mL) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>29.1 ± 37 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>32.2 ± 37.8 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>16.2 ± 30.9 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>0.07 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="269" pm="."><plain>Subsets of BP patients with or without mucosal involvement were compared and P-value was obtained using Chi2 tests for comparison between qualitative variables and nonparametric, Mann–Whitney tests for comparison between quantitative values. </plain></SENT>
</text></p><fn id="tfn4"><p><text><SENT sid="270" pm="."><plain>aPatients for whom serum anti-BP180 ELISA values were available. </plain></SENT>
</text></p></fn><fn id="tfn5"><p><text><SENT sid="271" pm="."><plain>bPatients for whom serum anti-BP230 ELISA values were available. </plain></SENT>
</text></p></fn><p><text><SENT sid="272" pm="."><plain>NA, not applicable; BP, bullous pemphigoid; ELISA, enzyme-linked immunosorbent assay. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="F3" position="float"><label>Figure 3</label><caption><p><text><SENT sid="273" pm="."><plain>Correlation of serum anti-BP180 NC16A titers with total BP Disease Area Index (BPDAI) (A,E), total skin BPDAI (B,F), blister/erosion BPDAI (C,G), and erythema/urticaria BPDAI (D,H) scores in bullous pemphigoid patients without (A–D) or with (E–H) mucosal involvement. </plain></SENT>
<SENT sid="274" pm="."><plain>The correlation coefficients and statistical significances were calculated according to Spearman’s correlation test and are summarized in Table 4. </plain></SENT>
</text></p></caption><graphic xlink:href="fimmu-09-00479-g003"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T4" position="float"><label>Table 4</label><caption><p><text><SENT sid="275" pm="."><plain>Correlation between BPDAI scores and serum anti-BP180 (A) or anti-BP230 (B) antibody titers in BP patients according to mucosal involvement. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>All BP patients </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>Patients without mucosal involvement </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>Patients with mucosal involvement </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="top" colspan="4" rowspan="1"><text><SENT sid="279" pm="."><plain>(A) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1"><text><SENT sid="280" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>Number of patients (n)a </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>94 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>76 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>18 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>Total BPDAI </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>r = 0.57 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>r = 0.62 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>r = 0.42 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>P = 0.09 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>Total skin BPDAI </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>r = 0.58 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>r = 0.63 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>r = 0.46 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>P = 0.06 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>Skin BPDAI: blisters/erosions </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>r = 0.46 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>r = 0.52 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>r = 0.26 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>P = 0.30 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>Skin BPDAI: erythema/urticaria </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>r = 0.52 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>r = 0.53 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>r = 0.52 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>P &lt; 0.0001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>P = 0.03 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>Mucosal BPDAI </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>r = 0.07 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>NA </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>r = 0.15 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>P = 0.48 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>NA </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>P = 0.55 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1"><text><SENT sid="320" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1"><text><SENT sid="321" pm="."><plain>(B) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1"><text><SENT sid="322" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>Number of patients (n)b </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>93 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>75 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>18 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>Total BPDAI </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>r = −0.01 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>r = 0.05 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>r = 0.04 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>P = 0.93 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>P = 0.69 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>P = 0.89 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>Total skin BPDAI </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>r = 0.001 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>r = 0.06 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>r = 0.02 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>P = 0.99 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>P = 0.63 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>P = 0.94 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>Skin BPDAI: blisters/erosions </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>r = 0.03 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>r = 0.11 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>r = −0.05 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>P = 0.76 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>P = 0.33 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>P = 0.86 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>Skin BPDAI: erythema/urticaria </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>r = 0.01 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>r = −0.01 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>r = 0.21 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>P = 0.89 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>P = 0.9 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>P = 0.41 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>Mucosal BPDAI </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>r = −0.20 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>NA </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>r = −0.26 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>P = 0.06 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>NA </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>P = 0.31 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="362" pm="."><plain>Spearman’s correlation coefficient was used to explore the relationship between BPDAI score and serum autoantibody titers. </plain></SENT>
</text></p><fn id="tfn6"><p><text><SENT sid="363" pm="."><plain>aPatients for whom serum anti-BP180 ELISA values were available. </plain></SENT>
</text></p></fn><fn id="tfn7"><p><text><SENT sid="364" pm="."><plain>bPatients for whom serum anti-BP230 ELISA values were available. </plain></SENT>
</text></p></fn><p><text><SENT sid="365" pm="."><plain>NA, not applicable; BP, bullous pemphigoid; BPDAI, BP Disease Area Index; ELISA, enzyme-linked immunosorbent assay. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="366" pm="."><plain>In BP patients with mucosal involvement at baseline, anti-BP180 ELISA values were only correlated with the erythema/urticaria BPDAI score (P = 0.03). </plain></SENT>
<SENT sid="367" pm="."><plain>Within this subgroup of BP patients, only a correlation tendency was observed with the total BPDAI score (P = 0.09) and the skin BPDAI score (P = 0.06), whereas no correlation could be drawn with the blister/erosion BPDAI score (P = 0.30) (Figures 3E–H, Table 4A). </plain></SENT>
<SENT sid="368" pm="."><plain>Finally, no correlation was found between the mucous membrane part of BPDAI score and the anti-BP180-NC16A ELISA values. </plain></SENT>
</text></p><p><text><SENT sid="369" pm="."><plain>Anti-BP230 antibodies were found in the serum of 44 BP patients (47.3%) with a mean titer of 29.1 ± 37 U/mL (Table 3). </plain></SENT>
<SENT sid="370" pm="."><plain>Interestingly, 39 BP patients without mucosal involvement (52%) but only 5 among BP patients with mucosal involvement (27.8%) had a positive anti-BP230 ELISA value (P = 0.06). </plain></SENT>
<SENT sid="371" pm="."><plain>Such a difference tendency was also observed when analyzing the anti-BP230 mean titer (32.2 ± 37.8 and 16.2 ± 30.9 U/mL; P = 0.07, respectively) (Table 3). </plain></SENT>
<SENT sid="372" pm="."><plain>At baseline, anti-BP230 antibody serum concentrations were correlated with none of the BPDAI scores within these two groups (Table 4B). </plain></SENT>
</text></p></sec><sec id="S3-4"><title><text><SENT sid="373" pm="."><plain>Factors Associated with Mucosal Involvement in BP </plain></SENT>
</text></title><p><text><SENT sid="374" pm="."><plain>In univariate analysis, clinical features associated with mucosal involvement at baseline were a number of daily new blisters &gt;10 (P = 0.02), a higher total, skin and blister/erosion BPDAI (P = 0.004, P = 0.02, P = 0.001, respectively), and a severe disease according BPDAI (P = 0.04). </plain></SENT>
<SENT sid="375" pm="."><plain>The absence of anti-BP230 autoantibody also showed a tendency of association with a mucosal involvement (P = 0.08). </plain></SENT>
<SENT sid="376" pm="."><plain>By contrast, univariate analysis revealed no relationship between anti-BP180 autoantibody serum concentration and mucosal involvement. </plain></SENT>
<SENT sid="377" pm="."><plain>In multivariate analysis, the absence of serum anti-BP230 autoantibody was the only factor independently associated with mucosal involvement (OR 7.8; 95% CI, 3.1–19.6) (P &lt; 0.0001). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="S4"><title><text><SENT sid="378" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="379" pm="."><plain>This study is the first one to compare at baseline the clinical characteristics by means of the BPDAI score along with the concentrations of anti-BP180 and anti-BP230 antibodies in BP patients with and without mucosal involvement. </plain></SENT>
<SENT sid="380" pm="."><plain>Analysis of separate and independent BPDAI sub-scores highlighted that skin lesions, more specifically blisters, and erosions were more substantial in patients with mucosal involvement than in typical BP. </plain></SENT>
<SENT sid="381" pm="."><plain>Such clinical characteristics were associated with the absence of anti-BP230 autoantibody in the serum of BP patients with mucosal involvement. </plain></SENT>
<SENT sid="382" pm="."><plain>Furthermore, we showed that mucosal lesions are clinically mainly related to disease severity, but not only. </plain></SENT>
<SENT sid="383" pm="."><plain>Altogether, our results suggest that compared to the classical pathophysiological processes previously defined in BP (12, 16, 17, 24, 33–36), specific immunological mechanisms should be triggered to end with mucosal lesions. </plain></SENT>
</text></p><p><text><SENT sid="384" pm="."><plain>In BP patients with mucosal involvement, skin and mucosal lesions are likely to concomitantly occur during the disease process. </plain></SENT>
<SENT sid="385" pm="."><plain>Although our results showed that mucosal involvement in BP was associated with disease severity, we also observed mucosal involvement in BP patient with mild disease. </plain></SENT>
<SENT sid="386" pm="."><plain>Actually, there was a broad distribution of total BPDAI score among BP patients with mucosal involvement, but the percentage of patients with mucosal involvement increased along with the BPDAI values (Figure 1C). </plain></SENT>
<SENT sid="387" pm="."><plain>This suggests that mucous membrane involvement in patients with mild BP is not just a consequence of the extent or severity of the disease, and therefore that some BP patients are more prone to develop mucosal lesions than others. </plain></SENT>
<SENT sid="388" pm="."><plain>Thus, we can speculate that specific biological/immunological mechanisms responsible for these lesions are activated in those BP patients. </plain></SENT>
<SENT sid="389" pm="."><plain>This further raised the question of the event on which a break of tolerance outside of the skin tissue could originate. </plain></SENT>
<SENT sid="390" pm="."><plain>Occurrence of mucosal lesions in some patients with BP recalls the variation in the number of sites involved in patients with mucous membrane pemphigoid (37). </plain></SENT>
<SENT sid="391" pm="."><plain>Previous study suggested that regulatory T (Treg) cells play an indispensable role in maintaining self-tolerance in BP leading to an increase in autoreactive Th2, Th1, and B cells that can recognize different domains of BP180 (38–40). </plain></SENT>
<SENT sid="392" pm="."><plain>The role of Treg cells in pemphigoid diseases was further demonstrated by mean of mice models (41). </plain></SENT>
<SENT sid="393" pm="."><plain>Although Treg cells account for less than 10% of peripheral CD4+ T cells, recent studies have reported that tissue resident Treg cells can even control non-immunological processes. </plain></SENT>
<SENT sid="394" pm="."><plain>Both Treg types demonstrated plasticity and can convert to Th17 cells according to the cytokine environment (42). </plain></SENT>
<SENT sid="395" pm="."><plain>In this line, we and other groups demonstrated the presence of cytokines such as IL-1, IL-6, IL-23, TGFβ, etc, in BP skin lesions. </plain></SENT>
<SENT sid="396" pm="."><plain>We also demonstrated that the cytokines panel more likely originated from BP epiphenomenon that still remained to be elucidated (26). </plain></SENT>
<SENT sid="397" pm="."><plain>Such variations could account for variations in a deficit in Treg cells and favor the development of tissue damages. </plain></SENT>
<SENT sid="398" pm="."><plain>In turn, skin remodeling could impact on both the number and the Treg homing at different levels of the skin compartments. </plain></SENT>
<SENT sid="399" pm="."><plain>Although aging has been associated with a loss of central immune tolerance in elderly patients as in BP (43), further investigations are now required to determine the events specifically responsible for the mucosal involvement in patients with BP, especially of the oral cavity. </plain></SENT>
</text></p><p><text><SENT sid="400" pm="."><plain>Although the analysis of skin BPDAI highlighted an increase in the blisters/erosions activity in BP patients with mucosal involvement, serum titers of autoantibodies directed against BP180-NC16A, the dominant autoantigen in BP, were not different between patients with and without mucosal involvement. </plain></SENT>
<SENT sid="401" pm="."><plain>Of note, Hofmann et al. showed that the presence of autoantibodies against both the BP180 N- and C-terminal of the ectodomain was associated with the presence of mucosal lesions (44). </plain></SENT>
<SENT sid="402" pm="."><plain>Then, Di Zenzo et al. (21) and Mariotti et al. (45) found that autoantibody reactivity against three extracellular epitopes of BP180 (NC16A, AA 1,080–1,107 and AA 1,331–1,404) appeared to be related to the presence of both skin and mucosal involvement in BP patients. </plain></SENT>
<SENT sid="403" pm="."><plain>By contrast, in our study, the uni- and multivariate analysis highlighted that the absence of anti-BP230 antibody was the only factor independently associated with mucosal involvement in BP. </plain></SENT>
<SENT sid="404" pm="."><plain>This unconventional result could imply that the immune response may be shifted toward other autoantibodies in those BP patients with mucosal involvement which could be related to a lower threshold of tolerance breakdown in line with a reduced level of Treg cells or of Treg homing as mentioned above. </plain></SENT>
<SENT sid="405" pm="."><plain>Based on a recent publication (20), we can hypothesize that the loss of immune tolerance curbs both the innate and the adaptive immune responses, which leads to the release of a specific panel of proteases associated with blister formation and tissue remodeling, and subsequently to a shift of the epitope targeted as compared with the classical pathophysiological mechanisms associated with BP. </plain></SENT>
<SENT sid="406" pm="."><plain>Altogether, this could be reflected by a reduced activity of the adaptive immune response toward the hemidesmosomal proteins of the basal keratinocyte layer and an increased activity toward the antigenic cryptic domains of molecules involved in the anchoring of those basal keratinocyte to the basal membrane structure. </plain></SENT>
<SENT sid="407" pm="."><plain>To address those mechanisms, it would be relevant to compare in future prospective studies the number and the activity of Treg in biopsy specimens from either skin or mucosa BP lesions with others samples collected from patients with inflammatory non-autoimmune diseases. </plain></SENT>
</text></p><p><text><SENT sid="408" pm="."><plain>The presence of other autoantibodies may interfere with the classical pathophysiological process of BP (12, 16, 17, 24, 33–36, 46). </plain></SENT>
<SENT sid="409" pm="."><plain>In BP patients without mucosal involvement, the serum concentration of anti-BP180 NC16A autoantibodies was well correlated with both the skin erythema/urticaria and the blisters/erosions BPDAI scores, which is in line with the fact that anti-BP180 autoantibody binding onto their target induced an inflammatory response leading to blister formation (14–18). </plain></SENT>
<SENT sid="410" pm="."><plain>By contrast, the correlation between anti-BP180 autoantibody titer and the skin blisters/erosions BPDAI score was not evidenced for BP patients with mucosal involvement. </plain></SENT>
<SENT sid="411" pm="."><plain>Of note, the BPDAI investigated the presence of both blisters and erosions. </plain></SENT>
<SENT sid="412" pm="."><plain>Thus, considering that the number of daily new blisters only displayed a higher tendency in BP patients with mucosal involvement, the highly significant difference in the BPDAI scores associated to blisters and erosions lesions may be related to the presence of erosions rather than to new blisters. </plain></SENT>
<SENT sid="413" pm="."><plain>This implies that the mechanisms leading to skin blisters/erosions and maybe to mucosal involvement too, rely on either different or additional trigger than anti-BP180-NC16A autoantibodies in BP patients with mucosal lesion. </plain></SENT>
<SENT sid="414" pm="."><plain>It was proposed that differential epitope recognition of BP180 could be associated with distinct clinical severity (5). </plain></SENT>
<SENT sid="415" pm="."><plain>However, additional studies are necessary to define the panel of autoantibodies associated with BP with mucosal lesions, to decipher the pathogenic role of these autoantibodies as well the immunologic mechanisms associated to their production. </plain></SENT>
</text></p><p><text><SENT sid="416" pm="."><plain>Several limitations of the study are to be acknowledged, mainly its relatively limited number of BP patients with mucosal involvement. </plain></SENT>
<SENT sid="417" pm="."><plain>However, the prospective collection of clinical data including BPDAI assessment allowed a good evaluation of the percentage of BP patients with mucosal involvement, which was very close to results from previous large series of BP patients (5, 6, 21, 32, 44, 45) and from a recent retrospective study performed in our dermatology department (manuscript under consideration). </plain></SENT>
<SENT sid="418" pm="."><plain>Another weakness is the lack of investigations regarding biopsy specimens or BFs from oral mucous membrane for pathophysiological purpose. </plain></SENT>
<SENT sid="419" pm="."><plain>Unfortunately, recent intact oral blisters were rare and too transient for an effective, systematic sampling. </plain></SENT>
<SENT sid="420" pm="."><plain>To avoid biases, our present results were based on clinical or biological data which could systematically be collected in all consecutive patients. </plain></SENT>
<SENT sid="421" pm="."><plain>Although we observed that mucosal involvement also occurred in patients with mild or moderate disease, we here showed that mucosal involvement was more frequent in patients with severe BP according to the BPDAI score. </plain></SENT>
<SENT sid="422" pm="."><plain>Actually, in those severe BP patients, mucosal involvement could represent a severity criterion but not a clinical atypia. </plain></SENT>
<SENT sid="423" pm="."><plain>Considering all elements discussed above, further investigations should help defining the pathophysiological particularities of severe BP patients with mucosal involvement. </plain></SENT>
<SENT sid="424" pm="."><plain>Finally, in patients with moderate or minimal BP disease, other diagnoses could be considered, including anti-P200 pemphigoid and epidermolysis bullosa acquisita, which was very unlikely in our present series since indirect immunofluorescence on salt-split skin was either positive with labeling of the epidermal side of the cleavage or negative. </plain></SENT>
<SENT sid="425" pm="."><plain>The latter BP patients may represent an interesting subset of patients to identify in future studies the specific mechanisms responsible for mucous membrane lesions with the ultimate goal to propose innovative targeted therapy to preserve the quality of life for those elderly fragile patients. </plain></SENT>
</text></p></sec></SecTag><sec id="S5"><title><text><SENT sid="426" pm="."><plain>Ethics Statement </plain></SENT>
</text></title><p><text><SENT sid="427" pm="."><plain>This study was carried out in accordance with the recommendations of the “Commission Nationale de l’Informatique et des libertés (CNIL, authorization DR-2013-320)” and approved by the Ethic Committee of the University Hospital of Reims. </plain></SENT>
<SENT sid="428" pm="."><plain>All subjects gave written informed consent in accordance with the Declaration of Helsinki. </plain></SENT>
</text></p></sec><SecTag type="AUTH_CONT"><sec id="S6"><title><text><SENT sid="429" pm="."><plain>Author Contributions </plain></SENT>
</text></title><p><text><SENT sid="430" pm="."><plain>FA, PB, and B-NP designed the study. </plain></SENT>
<SENT sid="431" pm="."><plain>AC, CM, GG, SJ, and CB performed experiments and analyzed clinical and biological data. </plain></SENT>
<SENT sid="432" pm="."><plain>AC, FA, and PB wrote the manuscript. </plain></SENT>
<SENT sid="433" pm="."><plain>All authors critically evaluated the data and approved the final version for publication. </plain></SENT>
</text></p></sec></SecTag><SecTag type="COMP_INT"><sec id="S7"><title><text><SENT sid="434" pm="."><plain>Conflict of Interest Statement </plain></SENT>
</text></title><p><text><SENT sid="435" pm="."><plain>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="436" pm="."><plain>We thank Maizières M., Ph.D., for technical support during the study. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><SecTag type="ACK_FUND"><fn fn-type="financial-disclosure"><p><text4fund><text><SENT sid="437" pm="."><plain>Funding. This work was supported by the French Department of Health’s “Projet Hospitalier de Recherche Clinique (PHRC) Interregional” 2012, and by the university of Reims Champagne-Ardenne. </plain></SENT>
<SENT sid="438" pm="."><plain>The funding source had no role in the design and conduct of the study, collection, management, analysis, and interpretation of data. </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="439" pm="."><plain>1BernardPAntonicelliF. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol (2017) 18(4):513–28.10.1007/s40257-017-0264-2<?supplied-pmid 28247089?>28247089 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="440" pm="."><plain>2StanleyJRTanakaTMuellerSKlaus-KovtunVRoopD. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients’ autoantibodies. J Clin Invest (1988) 82(6):1864–70.10.1172/JCI113803<?supplied-pmid 2461961?>2461961 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="441" pm="."><plain>3GiudiceGJEmeryDJDiazLA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol (1992) 99(3):243–50.10.1111/1523-1747.ep12616580<?supplied-pmid 1324962?>1324962 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="442" pm="."><plain>4ZillikensDRosePABaldingSDLiuZOlague-MarchanMDiazLA Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol (1997) 109(4):573–9.10.1111/1523-1747.ep12337492<?supplied-pmid 9326393?>9326393 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="443" pm="."><plain>5Thoma-UszynskiSUterWSchwietzkeSSchulerGBorradoriLHertlM. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol (2006) 176(3):2015–23.10.4049/jimmunol.176.3.2015<?supplied-pmid 16424234?>16424234 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="444" pm="."><plain>6Di ZenzoGThoma-UszynskiSFontaoLCalabresiVHofmannSCHellmarkT Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol (2008) 128(3):415–26.10.1016/j.clim.2008.04.012<?supplied-pmid 18571472?>18571472 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="445" pm="."><plain>7JolyPBaricaultSSparsaABernardPBédaneCDuvert-LehembreS Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol (2012) 132(8):1998–2004.10.1038/jid.2012.35<?supplied-pmid 22418872?>22418872 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="446" pm="."><plain>8BernardPVaillantLLabeilleBBedaneCArbeilleBDenoeuxJP Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. </plain></SENT>
<SENT sid="447" pm="."><plain>Bullous Diseases French Study Group. Arch Dermatol (1995) 131(1):48–52.10.1001/archderm.1995.01690130050009<?supplied-pmid 7826096?>7826096 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="448" pm="."><plain>9MurrellDFDanielBSJolyPBorradoriLAmagaiMHashimotoT Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol (2012) 66(3):479–85.10.1016/j.jaad.2011.06.03222056920 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="449" pm="."><plain>10VaillantLBernardPJolyPProstCLabeilleBBedaneC Evaluation of clinical criteria for diagnosis of bullous pemphigoid. </plain></SENT>
<SENT sid="450" pm="."><plain>French Bullous Study Group. Arch Dermatol (1998) 134(9):1075–80.10.1001/archderm.134.9.1075<?supplied-pmid 9762017?>9762017 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="451" pm="."><plain>11KormanN. Bullous pemphigoid. J Am Acad Dermatol (1987) 16(5 Pt 1):907–24.10.1016/S0190-9622(87)70115-7<?supplied-pmid 3294944?>3294944 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="452" pm="."><plain>12Di ZenzoGMarazzaGBorradoriL. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol (2007) 23:257–88.10.1016/j.yadr.2007.07.013<?supplied-pmid 18159905?>18159905 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="453" pm="."><plain>13SchmidtEZillikensD. Pemphigoid diseases. Lancet (2013) 381(9863):320–32.10.1016/S0140-6736(12)61140-4<?supplied-pmid 23237497?>23237497 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="454" pm="."><plain>14GammonWRMerrittCCLewisDMSamsWMCarloJRWheelerCE. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol (1982) 78(4):285–90.10.1111/1523-1747.ep12507222<?supplied-pmid 7040558?>7040558 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="455" pm="."><plain>15SitaruCSchmidtEPetermannSMunteanuLSBröckerE-BZillikensD. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol (2002) 118(4):664–71.10.1046/j.1523-1747.2002.01720.x<?supplied-pmid 11918714?>11918714 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="456" pm="."><plain>16LiuZDiazLATroyJLTaylorAFEmeryDJFairleyJA A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest (1993) 92(5):2480–8.10.1172/JCI116856<?supplied-pmid 7693763?>7693763 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="457" pm="."><plain>17NishieWSawamuraDGotoMItoKShibakiAMcMillanJR Humanization of autoantigen. Nat Med (2007) 13(3):378–83.10.1038/nm1496<?supplied-pmid 17322897?>17322897 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="458" pm="."><plain>18UjiieHShibakiANishieWSawamuraDWangGTateishiY A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol (2010) 184(4):2166–74.10.4049/jimmunol.0903101<?supplied-pmid 20089696?>20089696 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="459" pm="."><plain>19LudwigRJVanhoorelbekeKLeypoldtFKayaZBieberKMcLachlanSM Mechanisms of autoantibody-induced pathology. Front Immunol (2017) 8:60310.3389/fimmu.2017.0060328620373 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="460" pm="."><plain>20BieberKKogaHNishieW. In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseases. Exp Dermatol (2017) 26(12):1163–70.10.1111/exd.13415<?supplied-pmid 28833569?>28833569 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="461" pm="."><plain>21Di ZenzoGGrossoFTerracinaMMariottiFDe PitàOOwaribeK Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol (2004) 122(1):103–10.10.1046/j.0022-202X.2003.22126.x<?supplied-pmid 14962097?>14962097 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="462" pm="."><plain>22SchmidtEdella TorreRBorradoriL. Clinical features and practical diagnosis of bullous pemphigoid. Immunol Allergy Clin North Am (2012) 32(2):217–232, v.10.1016/j.iac.2012.04.002<?supplied-pmid 22560135?>22560135 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="463" pm="."><plain>23NiimiYPawankarRKawanaS. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol (2006) 139(2):104–13.10.1159/000090385<?supplied-pmid 16374020?>16374020 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="464" pm="."><plain>24VerraesSHornebeckWPoletteMBorradoriLBernardP. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol (2001) 117(5):1091–6.10.1046/j.0022-202x.2001.01521.x<?supplied-pmid 11710917?>11710917 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="465" pm="."><plain>25Le JanSPléeJVallerandDDupontADelanezEDurlachA Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol (2014) 134(12):2908–17.10.1038/jid.2014.263<?supplied-pmid 24945093?>24945093 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="466" pm="."><plain>26PléeJLe JanSGiustinianiJBarbeCJolyPBedaneC Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep (2015) 5:18001.10.1038/srep18001<?supplied-pmid 26656739?>26656739 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="467" pm="."><plain>27GiustiDGatouillatGLe JanSPléeJBernardPAntonicelliF Eosinophil cationic protein (ECP), a predictive marker of bullous pemphigoid severity and outcome. Sci Rep (2017) 7(1):483310.1038/s41598-017-04687-528684769 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="468" pm="."><plain>28Lévy-SitbonCBarbeCPleeJGoeldelA-LAntonicelliFReguiaïZ Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients. Dermatology (2014) 229(2):116–22.10.1159/000362717<?supplied-pmid 25011586?>25011586 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="469" pm="."><plain>29KobayashiMAmagaiMKuroda-KinoshitaKHashimotoTShirakataYHashimotoK BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci (2002) 30(3):224–32.10.1016/S0923-1811(02)00109-3<?supplied-pmid 12443845?>12443845 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="470" pm="."><plain>30Tsuji-AbeYAkiyamaMYamanakaYKikuchiTSato-MatsumuraKCShimizuH. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci (2005) 37(3):145–9.10.1016/j.jdermsci.2004.10.007<?supplied-pmid 15734283?>15734283 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="471" pm="."><plain>31YoshidaMHamadaTAmagaiMHashimotoKUeharaRYamaguchiK Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci (2006) 41(1):21–30.10.1016/j.jdermsci.2005.11.002<?supplied-pmid 16364599?>16364599 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="472" pm="."><plain>32CharneuxJLorinJVitryFAntonicelliFReguiaiZBarbeC Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol (2011) 147(3):286–91.10.1001/archdermatol.2011.23<?supplied-pmid 21422334?>21422334 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="473" pm="."><plain>33HiroseMReckeABeckmannTShimizuAIshikoABieberK Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol (2011) 187(3):1176–83.10.4049/jimmunol.1100596<?supplied-pmid 21705619?>21705619 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="474" pm="."><plain>34SchulzeFSBeckmannTNimmerjahnFIshikoACollinMKöhlJ Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. Am J Pathol (2014) 184(8):2185–96.10.1016/j.ajpath.2014.05.007<?supplied-pmid 25043618?>25043618 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="475" pm="."><plain>35KasperkiewiczMZillikensD. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol (2007) 33(1–2):67–77.10.1007/s12016-007-0030-y<?supplied-pmid 18094948?>18094948 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="476" pm="."><plain>36KasperkiewiczMZillikensDSchmidtE Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity (2012) 45(1):55–70.10.3109/08916934.2011.60644721923615 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="477" pm="."><plain>37ZehouORaynaudJ-JLe Roux-VilletCAlexandreMAirineiGPascalF Oesophageal involvement in 26 consecutive patients with mucous membrane pemphigoid. Br J Dermatol (2017) 177(4):1074–85.10.1111/bjd.15592<?supplied-pmid 28417469?>28417469 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="478" pm="."><plain>38AntigaEQuaglinoPVolpiWPieriniIDel BiancoEBianchiB Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid. J Eur Acad Dermatol Venereol (2014) 28(2):222–30.10.1111/jdv.12091<?supplied-pmid 23331964?>23331964 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="479" pm="."><plain>39QuaglinoPAntigaEComessattiACaproniMNardòTPontiR Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients. Arch Dermatol Res (2012) 304(8):639–45.10.1007/s00403-012-1213-9<?supplied-pmid 22310732?>22310732 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="480" pm="."><plain>40LiuYLiLXiaY BP180 is critical in the autoimmunity of bullous pemphigoid. Front Immunol (2017) 8:175210.3389/fimmu.2017.0175229276517 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="481" pm="."><plain>41BieberKSunSWitteMKasprickABeltsiouFBehnenM Regulatory T cells suppress inflammation and blistering in pemphigoid diseases. Front Immunol (2017) 8:162810.3389/fimmu.2017.0162829225603 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="482" pm="."><plain>42ZhouXTangJCaoHFanHLiB. Tissue resident regulatory T cells: novel therapeutic targets for human disease. Cell Mol Immunol (2015) 12(5):543–52.10.1038/cmi.2015.23<?supplied-pmid 25891216?>25891216 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="483" pm="."><plain>43DorshkindKMontecino-RodriguezESignerRAJ. The ageing immune system: is it ever too old to become young again? Nat Rev Immunol (2009) 9(1):57–62.10.1038/nri2471<?supplied-pmid 19104499?>19104499 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="484" pm="."><plain>44HofmannSCThoma-UszynskiSStauberASchulerGHertlMHunzikerT Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol (2002) 119(5):1065–73.10.1046/j.1523-1747.2002.19529.x<?supplied-pmid 12445194?>12445194 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="485" pm="."><plain>45MariottiFGrossoFTerracinaMRuffelliMCordiali-FeiPSeraF Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol (2004) 151(5):1004–10.10.1111/j.1365-2133.2004.06245.x<?supplied-pmid 15541078?>15541078 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="486" pm="."><plain>46GoletzSZillikensDSchmidtE. Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. Exp Dermatol (2017) 26(12):1154–62.10.1111/exd.13446<?supplied-pmid 28887824?>28887824 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
